Bruce A Feinberg, DO

$Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States$

Research Reports

Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States

02/18/2020

Andrew J Klink, PhD, MPH

Chadi Nabhan, MD, MBA, FACP

Choo Hyung Lee, MS

JaLyna Laney, RN, OCN

Yin Yang, MS

Anna G Purdum, PharmD, MS

Bruce A Feinberg, DO

Abstract: Given new therapeutic advances that are potentially curative in diffuse large B-cell lymphoma (DLBCL), it is important to understand what has been observed to date in this population to assess improvement...

...

02/18/2020

Journal of Clinical Pathways

Research Reports

Community Oncologists` Perception and Acceptance of Biosimilars in Oncology

09/13/2018

Chadi Nabhan, MD, MBA, FACP

Yolaine Jeune-Smith, PhD

Amy Valley, PharmD

Bruce A Feinberg, DO

Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...

...

09/13/2018

Journal of Clinical Pathways

Counterpoint

CAR-T Therapies: Placing Patient Safety First

08/22/2018

Chadi Nabhan, MD, MBA, FACP

Bruce A Feinberg, DO

The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...

The...

08/22/2018

Journal of Clinical Pathways

Research Reports

KRAS/RAS Testing Is Associated With Reduced Risk of Treatment Discontinuation in Patients With Metastatic Colorectal Cancer

08/22/2018

Alexandra Christodoulopoulou, MSc

Bruce A Bach, MD, PhD

Andrew J Klink, PhD, MPH

Guy Hechmati, MD, MSc

Urvi Mujumdar, MPH

Bruce A Feinberg, DO

Marwan Fakih, MD

Abstract: Current clinical guidelines recommend that all patients with metastatic colorectal cancer (mCRC) have tumor tissue genotyped for RAS mutations. This study aimed to evaluate patient characteristics and...

...

08/22/2018

Journal of Clinical Pathways

Feature

Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond

03/23/2017

Chadi Nabhan, MD, MBA, FACP

Sandeep Parsad, PharmD, BCOP

Bruce A Feinberg, DO

Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...

...

03/23/2017

Journal of Clinical Pathways